Revelation Biosciences In... (REVB)
Bid | 2.57 |
Market Cap | 2.33M |
Revenue (ttm) | 14.23K |
Net Income (ttm) | -7.94B |
EPS (ttm) | -87.68 |
PE Ratio (ttm) | -0.03 |
Forward PE | -0.13 |
Analyst | n/a |
Ask | 2.81 |
Volume | 10,408 |
Avg. Volume (20D) | 246,745 |
Open | 2.66 |
Previous Close | 2.70 |
Day's Range | 2.51 - 2.80 |
52-Week Range | 2.36 - 60.80 |
Beta | 0.18 |
About REVB
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is a...

2 weeks ago · businesswire.com
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth ConferenceSAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...

1 month ago · businesswire.com
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing ApprovalSAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflamm...